{"filing":{"accession_number":"0001731122-26-001020","cik":"0001553788","ticker":"SBEVW","company_name":"SPLASH BEVERAGE GROUP, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"e7828_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/e7828_8k.htm"},"events":[{"id":25227,"run_id":22891,"accession_number":"0001731122-26-001020","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Splash Beverage Group announced entry into a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil® through FDA veterinary regulatory pathways. This is a material operational and strategic partnership involving a defined development program with milestone-based funding, regulatory execution, and commercialization rights retention. While it involves a partnership and capital commitment, it does not fit the specific categories of M\u0026A activity (no acquisition/merger/change of control), debt issuance, or other named financial events—it is a strategic operational collaboration that would affect investor assessment of the company's business direction and capital allocation.","company_name":"SPLASH BEVERAGE GROUP, INC.","ticker":"SBEVW","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25996,"accession_number":"0001731122-26-001020","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Splash Beverage Group announced entry into a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil® through FDA veterinary regulatory pathways. This is a material operational and strategic partnership involving a defined development program with milestone-based funding, regulatory execution, and commercialization rights retention. While it involves a partnership and capital commitment, it does not fit the specific categories of M\u0026A activity (no acquisition/merger/change of control), debt issuance, or other named financial events—it is a strategic operational collaboration that would affect investor assessment of the company's business direction and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:48.610129+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25996,"accession_number":"0001731122-26-001020","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Splash Beverage Group announced entry into a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil® through FDA veterinary regulatory pathways. This is a material operational and strategic partnership involving a defined development program with milestone-based funding, regulatory execution, and commercialization rights retention. While it involves a partnership and capital commitment, it does not fit the specific categories of M\u0026A activity (no acquisition/merger/change of control), debt issuance, or other named financial events—it is a strategic operational collaboration that would affect investor assessment of the company's business direction and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:48.610129+00:00","company_name":"SPLASH BEVERAGE GROUP, INC.","ticker":"SBEVW","filing_date":"2026-08-05"}]}